Genovis will attend several conferences in May –June 2011


 

Genovis markets products that accelerate the development of new drugs and imaging techniques. In May - June, the company will increase its marketing activities and participate in several conferences to present their products and respond to existing and new customers

Genovis will attend the ISMRM 2011 in Montreal, 7-13 May. In addition scientists from Medical Radiation Physics, Dept of Clinical Sciences Lund, Lund University Hospital will present results originating from collaboration with Genovis on multimodal nanoparticles.

http://www.ismrm.org/11/

Genovis nanoparticles for biomedical imaging, will be presented at the Nano Update 2011 in Helsingborg Sweden the 24th of May.  

http://www.b2match.eu/update2011

Genovis will be attending the 7th Annual Monoclonal Antibody Conference in London May 19-20. The event will take place at the The Thistle City Barbican Hotel. There will be Vendor Exhibits and Genovis will have a booth displayed to serve prospective clients with required information.

http://www.visiongain.com/Conference/296/7th-Annual-Monoclonal-Antibody-Conference

Genovis CEO, Sarah Fredriksson will present the rationale behind including upconverting nanoparticles in Genovis nanoproduct portfolio on the 31 st of May at the EuroNanoForum 2011. The conference is organized in Budapest, Hungary, starting on Monday the 30th of May and ending on Wednesday the 1st.  

http://www.euronanoforum2011.eu/

Genovis will show applications of its antibody modifying enzymes for mass spectrometry applications at ASMS 2011 in Denver Colorado USA, June 6-9.

http://www.asms.org

 

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 46 10 12 35 sarah.fredriksson@genovis.com

Genovis develops and designs smart nanoparticles for preclinical imaging and diagnostics and also develops and sells tools for modification of antibodies. Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission ( 46 (0)31 745 50 00) is the Company’s certified adviser.

About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North

Documents & Links